However, clinical trials showed the high sensitivity of lung cancer patients with low RRM1 expression to gemcitabine, and the chemotherapy scheme with gemcitabine is often used to treat the patients with low RRM1.3 This evidence concerns the gene RRM1 and lung carcinoma.